Current management of castrate-resistant prostate cancer

Current Oncology

Volumn 17, Issue SUPPL. 2, 2010, Pages

  Hotte, Sebastien J ^a   Saad, F ^b  

^a MCMASTER UNIVERSITY   (Canada)

^b CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

Castrate resistant prostate cancer; Systemic treatment

Indexed keywords

ABIRATERONE; ABIRATERONE ACETATE; ACETYLSALICYLIC ACID; ANDROGEN; ANTIANDROGEN; ANTINEOPLASTIC AGENT; BICALUTAMIDE; BISPHOSPHONIC ACID DERIVATIVE; CABAZITAXEL; CARBOPLATIN; CISPLATIN; DEXAMETHASONE; DOCETAXEL; ESTRAMUSTINE; ETOPOSIDE; GONADORELIN AGONIST; MITOXANTRONE; PLACEBO; PREDNISONE; PROSTATE SPECIFIC ANTIGEN; PROVENGE; SAMARIUM; STRONTIUM; TESTOSTERONE; UNCLASSIFIED DRUG; WARFARIN; ZOLEDRONIC ACID;

ABSENCE OF SIDE EFFECTS; ANDROGEN DEPRIVATION THERAPY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD TOXICITY; BONE DENSITY; BONE METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER PAIN; CANCER PALLIATIVE THERAPY; CASTRATE RESISTANT PROSTATE CANCER; CASTRATION; CHILL; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DRUG EFFICACY; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG POTENTIATION; DRUG SAFETY; DRUG SENSITIVITY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; HUMAN; JAW OSTEONECROSIS; LOW DRUG DOSE; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OSTEOLYSIS; OVERALL SURVIVAL; PROSTATE CANCER; PROTEIN BLOOD LEVEL; PROTEIN PHOSPHORYLATION; QUALITY OF LIFE; SURVIVAL TIME; THROMBOSIS; THROMBOSIS PREVENTION; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 78149488805     PISSN: None     EISSN: 17187729     Source Type: Journal    
DOI: 10.3747/co.v17i0.718     Document Type: Article

References (45)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin 2008;58:71-96.
2. Sharifi N, Dahut WL, Steinberg SM, et al. A retrospective study of the time to clinical endpoints for advanced prostate cancer. BJU Int 2005;96:985-9.
3. Mostaghel EA, Page ST, Lin DW, et al. Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: therapeutic implications for castrationresistant prostate cancer. Cancer Res 2007;67:5033-41.
4. Scher HI, Halabi S, Tannock I, et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 2008;26:1148-59.
5. Sciarra A, Cardi A, Di Silverio F. Antiandrogen monotherapy: recommendations for the treatment of prostate cancer. Urol Int 2004;72:91-8.
6. Cox RL, Crawford ED. Estrogens in the treatment of prostate cancer. J Urol 1995;154:1991-8.
7. Small EJ, Halabi S, Dawson NA, et al. Antiandrogen withdrawal alone or in combination with ketoconazole in androgenindependent prostate cancer patients: a phase iii trial (calgb 9583). J Clin Oncol 2004;22:1025-33.
8. Storlie JA, Buckner JC, Wiseman GA, Burch PA, Hartmann LC, Richardson RL. Prostate specific antigen levels and clinical response to low dose dexamethasone for hormone-refractory metastatic prostate carcinoma. Cancer 1995;76:96-100.
9. Hartmann R, Ehmer P, Haidar S, et al. Inhibition of CYP 17, a new strategy for treatment of prostate cancer. Arch Pharm (Weinheim) 2002;335:119-28.
10. De Bono JS, Attard G, Reid AH, et al. Antitumour activity of abiraterone acetate (aa), a CYP17 inhibitor of androgen synthesis, in chemotherapy naïve and docetaxel pre-treated castration resistant prostate cancer (crpc) [abstract 5005]. Proc Am Soc Clin Oncol 2008;26:. [Available online at: www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view& confID=55&abstractID=35800; cited June 11, 2010]
11. Danila DC, Rathkopf DE, Morris MJ, et al. Abiraterone acetate and prednisone in patients (Pts) with progressive metastatic castration resistant prostate cancer (crpc) after failure of docetaxel-based chemotherapy [abstract 5019]. Proc Am Soc Clin Oncol 2008;26:. [Available online at: www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view& confID=55&abstractID=31508; cited June 11, 2010]
12. Tannock IF, Osoba D, Stockler MR, et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative endpoints. J Clin Oncol 1996;14:1756-64.
13. Heng DY, Chi KN. Prednisone monotherapy in asymptomatic hormone refractory prostate cancer. Can J Urol 2006;13:3335-9.
14. Petrylak DP, Tangen CM, Hussain MHA, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004;351:1513-20.
15. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351:1502-12.
16. Winquist E, Waldron T, Berry S, Ernst DS, Hotte S, Lukka H. Non-hormonal systemic therapy in men with hormonerefractory prostate cancer and metastases: a systematic review from the Cancer Care Ontario Program in Evidence-Based Care's Genitourinary Cancer Disease Site Group. BMC Cancer 2006;6:112-30.
17. National Comprehensive Cancer Network (nccn). NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer V.2.2010. Fort Washington, PA: nccn; 2010. [Available online at: www.nccn.org/professionals/physician_gls/PDF/prostate.pdf (free registration required); cited June 16, 2010]
18. Higano CS, Schellhammer PF, Small EJ, et al. Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer 2009;115:3670-9.
19. Schellhammer PF, Higano C, Berger ER, et al. on behalf of the impact Study Investigators. A randomized, double-blind, placebo-controlled, multi-center, phase iii trial of sipuleucel-T in men with metastatic, androgen independent prostatic adenocarcinoma (aipc) [abstract LBA9]. Presented at the American Urological Association meeting; Chicago, IL; April 25-30, 2009. [Available online at www.aua2010.org/Attendees/lba09/lba9.pdf; cited June 18, 2010]
20. Michels J, Montemurro T, Murray N, Kollmannsberger C, Chi KN. First- and second-line chemotherapy with docetaxel or mitoxantrone in patients with hormone-refractory prostate cancer: does sequence matter? Cancer 2006;106:1041-6.
21. Oh WK, Manola J, Babcic V, Harnam N, Kantoff PW. Response to second-line chemotherapy in patients with hormone refractory prostate cancer receiving two sequences of mitoxantrone and taxanes. Urology 2006;67:1235-40.
22. Berthold DR, Pond GR, de Wit R, Eisenberger M, Tannock IF. Survival and psa response of patients in the tax 327 study who crossed over to receive docetaxel after mitoxantrone or vice versa. Ann Oncol 2008;19:1749-53.
23. Rosenberg JE, Weinberg VK, Kelly WK, et al. Activity of second-line chemotherapy in docetaxel-refractory hormonerefractory prostate cancer patients: randomized phase 2 study of ixabepilone or mitoxantrone and prednisone. Cancer 2007;110:556-63.
24. Berger ER, Ciuleanu T, Hart L, et al. Results of a randomized phase ii study of irofulven in hormone-refractory prostate cancer patients that have failed first-line docetaxel treatment [abstract 5068]. Proc Am Soc Clin Oncol 2007;25:. [Available online at: www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view& confID=47&abstractID=35021; cited June 11, 2010]
25. Beer TM, Ryan CW, Venner PM, et al. Intermittent chemotherapy in patients with metastatic androgen-independent prostate cancer: results from ascent, a double-blinded, randomized comparison of high-dose calcitriol plus docetaxel with placebo plus docetaxel. Cancer 2008;112:326-30.
26. Jankovic B, Beardsley E, Chi KN. Rechallenge with docetaxel as second-line chemotherapy in patients with metastatic hormone refractory prostate cancer (hrpc) after previous docetaxel: a population based analysis [abstract 196]. Proc Am Soc Clin Oncol Genitourin Symp 2008;:. [Available online at: www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view& confID=54&abstractID=20048; cited June 11, 2010]
27. Ansari J, Hussain SA, Zarkar A, Tanguay JS, Bliss J, Glaholm J. Docetaxel chemotherapy for metastatic hormone refractory prostate cancer as first-line palliative chemotherapy and subsequent re-treatment: Birmingham experience. Oncol Rep 2008;20:891-6.
28. Eymard J, Oudard S, Gravis G, et al. Docetaxel reintroduction in patients with metastatic castration-resistant docetaxelsensitive prostate cancer: a retrospective multicentre study. BJU Int 2010;:. [Epub ahead of print]
29. Di Lorenzo G, Buonerba C, Autorino R, De Placido S, Sternberg CN. Castration-resistant prostate cancer: current and emerging treatment strategies. Drugs 2010;70:983-1000.
30. Sartor AO, Oudard S, Ozguroglu M, et al. Cabazitaxel or mitoxantrone with prednisone in patients with metastatic castration-resistant prostate cancer (mcrpc) previously treated with docetaxel: final results of a multinational phase iii trial (tropic) [abstract 9]. Proc Am Soc Clin Oncol Genitourin Symp 2010;:. [Available online at: www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view& confID=73&abstractID=30560; cited June 11, 2010]
31. Wu JS, Wong RK, Lloyd NS, Johnston M, Bezjak A, Whelan T. Radiotherapy fractionation for the palliation of uncomplicated painful bone metastases-an evidence-based practice guideline. BMC Cancer 2004;4:71.
32. Diamond TH, Higano CS, Smith MR, Guise TA, Singer FR. Osteoporosis in men with prostate carcinoma receiving androgen-deprivation therapy: recommendations for diagnosis and therapies. Cancer 2004;100:892-9.
33. Preston DM, Torréns JI, Harding P, Howard RS, Duncan WE, McLeod DG. Androgen deprivation in men with prostate cancer is associated with an increased rate of bone loss. Prostate Cancer Prostatic Dis 2002;5:304-10.
34. Shahinian VB, Kuo YF, Freeman JL, Goodwin JS. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 2005;352:154-64.
35. Weinfurt KP, Li Y, Castel LD, et al. The significance of skeletal related events for the health-related quality of life of patients with metastatic prostate cancer. Ann Oncol 2005; 16:579-84.
36. Smith MR, McGovern FJ, Zietman AL, et al. Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N Engl J Med 2001;345:948-55.
37. Smith MR, Eastham J, Gleason DM, Shasha D, Tchekmedyian S, Zinner N. Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Urol 2003; 169:2008-12.
38. Saad F, Gleason DM, Murray R, et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone refractory prostate cancer. J Natl Cancer Inst 2004;96:879-82.
39. Aapro M, Abrahamsson PA, Body JJ, et al. Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel. Ann Oncol 2008;19:420-32.
40. Sarin J, DeRossi SS, Akintoye SO. Updates on bisphosphonates and potential pathobiology of bisphosphonate-induced jaw osteonecrosis. Oral Dis 2008;14:277-85.
41. Pazianas M, Miller P, Blumentals WA, Bernal M, Kothawala P. A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics. Clin Ther 2007;29:1548-58.
42. Migliorati CA, Siegel MA, Elting LS. Bisphosphonate-associated osteonecrosis: a long-term complication of bisphosphonate treatment. Lancet Oncol 2006;7:508-14.
43. Ullen A, Lennartsson L, Harmenberg U, et al. Additive/synergistic antitumoural effects on prostate cancer cells in vitro following treatment with a combination of docetaxel and zoledronic acid. Acta Oncol 2005;44:644-50.
44. Saad F, Markus R, Goessl C. Targeting the receptor activator of nuclear factor-κB (rank) ligand in prostate cancer bone metastases. BJU Int 2007;101:1071-5.
45. Smith MR, Egerdie B, Hernández Toriz N, et al. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med 2009;361:745-55.